EP. 2: Balstilimab in Advanced Cervical Cancer: Rationale and Key Efficacy Outcomes
November 30th 2021
Focusing on novel immune checkpoint inhibitors, Robert L. Coleman, MD, FACOG, FACS, breaks down preclinical and clinical data that support use of balstilimab in patients with advanced cervical cancer.